Validation of r(G4C2)exp-binding small molecules in vivo and c9FTD/ALS biomarker development

Medicine & Life Sciences

1. Amyotrophic Lateral Sclerosis 100%
2. Biomarkers 53%
3. Cell Nucleus Active Transport 18%
4. poly(glycyl-alanyl) 15%
5. Nucleocytoplasmic Transport Proteins 14%
6. Transcriptome 14%
7. Proteins 14%
8. Cerebrospinal Fluid 13%
9. Frontotemporal Dementia With Motor Neuron Disease 11%
10. RNA 10%
11. Nuclear Pore 10%
12. Clinical Trials 9%
13. Porins 9%
14. Pathology 9%
15. Patient Participation 8%
16. Alternative Splicing 8%
17. Preliminary Data 8%
18. Nuclear Proteins 7%
19. Therapeutics 6%
20. Yeasts 6%
21. Lymphocytes 5%